Indeed, beyond several changes regarding the total percentage of CD19+ B cells comprehending naive and memory phenotypes, as well as regulatory B subsets, increased circulating plasma cells were already described during highly effective MS treatments (39). This evidence concerns the gene CD19 and myeloid sarcoma.